CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them?
Anran Chen1, Ze-Yi Zheng2,3, Meenakshi Anurag2,3
1Research Oncology, Bayer, Cambridge, MA 02142, USA.
Abstract:
More than 70% of breast cancers are estrogen receptor-positive (ER+). Endocrine therapy that blocks estrogen signaling remains the cornerstone of treatment, yet relapses continue to affect many patients. Cyclin-dependent kinases 4 and 6 (CDK4/6) regulate the G1-S phase transition in the cell cycle, and pharmacological inhibition of this pathway has been successfully leveraged to reduce recurrence. CDK4/6 inhibitors combined with endocrine therapy are now the standard of care, although determining the optimal patient population for treatment remains a key challenge. A newly published study provides important insight, showing that loss of the NF1/neurofibromin tumor suppressor confers greater sensitivity to CDK4/6 inhibition, as these tumors rely heavily on CDK4/6 activity for survival under endocrine therapy.
Insights
Loss of the NF1 tumor suppressor gene increases sensitivity to CDK4/6 inhibitors in estrogen receptor-positive breast cancer. This finding helps identify patients who may benefit most from this targeted therapy combination.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Estrogen receptor-positive (ER+) breast cancer accounts for over 70% of cases.
- Endocrine therapy is a primary treatment, but cancer recurrence remains a significant issue.
- Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are used with endocrine therapy to reduce recurrence.
Purpose of the Study:
- To investigate the role of the NF1 tumor suppressor in response to CDK4/6 inhibition.
- To identify patient populations that may benefit from combined endocrine therapy and CDK4/6 inhibitors.
Main Methods:
- Analysis of tumor suppressor gene status, specifically NF1.
- Evaluation of cellular dependence on CDK4/6 activity.
- Assessment of sensitivity to CDK4/6 inhibitors in the context of endocrine therapy.
Main Results:
- Loss of the NF1 tumor suppressor confers increased sensitivity to CDK4/6 inhibitors.
- Tumors with NF1 loss exhibit heightened reliance on CDK4/6 for survival during endocrine therapy.
Conclusions:
- NF1 deficiency is a predictive biomarker for CDK4/6 inhibitor efficacy in ER+ breast cancer.
- Targeting CDK4/6 in NF1-deficient tumors may improve treatment outcomes and reduce recurrence.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:39Positive Regulator Molecules
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...